Tvardi Therapeutics Inc
Company Profile
Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USAT: +1 713 489-8654
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,886.96 | 0.18 | -0.00% |
| DAX 40 | 25,704.02 | 113.25 | 0.44% |
| Dow JONES (US) | 52,475.10 | 97.53 | 0.19% |
| FTSE 100 | 10,694.50 | 7.96 | 0.07% |
| HKSE | 23,048.73 | 46.10 | -0.20% |
| NASDAQ | 26,549.85 | 72.04 | 0.27% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,710.17 | 18.84 | 0.14% |
| S&P 500 | 7,743.98 | 21.38 | 0.28% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |